Rocketvax Collaborates with HALIX to Develop Next-Gen Nasal COVID-19 Vaccine

• Rocketvax AG has partnered with HALIX B.V. to advance the VIRUFLEX endemic readiness platform, enhancing global pandemic preparedness.

• The collaboration focuses on the development of Rocketvax’s next-generation nasal COVID-19 vaccine.

Rocketvax AG, a Swiss biotech leader, has teamed up with HALIX B.V., a top-tier Contract Development and Manufacturing Organization (CDMO), to bolster global pandemic readiness. The partnership will leverage Rocketvax’s innovative VIRUFLEX platform, designed to accelerate vaccine development in response to future pandemics.

The VIRUFLEX platform integrates cutting-edge vaccine technology, scalable production processes, and strong global partnerships to ensure rapid responses to emerging infectious diseases. As a strategic CDMO partner, HALIX will contribute expertise in GMP-grade manufacturing, viral vector production, and scalable vaccine production.

The collaboration also focuses on Rocketvax’s groundbreaking nasal COVID-19 vaccine, developed using its proprietary reverse genetic engineering technology. The vaccine offers several advantages over conventional vaccines, including nasal immunity, broad protein recognition, and prevention of virus transmission. Furthermore, it is stable at room temperature, simplifying storage and distribution.

This partnership is further supported by a collaboration with the U.S. National Institutes of Health (NIH), ensuring that Rocketvax’s vaccine candidates receive the necessary clinical development and support for global accessibility.

“We are thrilled to partner with HALIX to bring the VIRUFLEX platform to life and revolutionize global pandemic readiness,” said Vladimir Cmiljanovic, CEO of Rocketvax AG. Dr. Lutz Hilbrich, CEO of HALIX, expressed his support, stating, “The VIRUFLEX platform exemplifies the innovative spirit needed to address global health challenges.”